Ruha Private Equity's Stake in LabGenomics Drops 6.72% Points… Increased Shareholder Risk from Early Redemption Exercise and Collateral Pledge
Ruha Private Equity, the largest shareholder group, reduced its stake in LabGenomics from 30.93% to 24.21%, a decrease of 6.72 percentage points. The reduction of approximately 7.75 million shares stemmed mainly from early redemption of convertible bonds (about 7.33 million shares), along with stock option cancellations due to executive resignations (about 0.42 million shares) and a small open-market sale (about 0.03 million shares).
The key driver was the early redemption of convertible bonds held by special relation Ruha Galacticos (convertible into about 7.33 million shares), eliminating conversion rights. Concurrently, Ruha Galacticos pledged approximately 12 million shares (14.71% stake) and 7.33 million convertible bonds (8.98% stake) as collateral to Stick Litmus for a loan of 33 billion won.
The secured loan carries a yield-to-maturity of 9.0% per annum and a fixed coupon of 1.0%, with a collateral maintenance ratio of 117.65%. This indicates the largest shareholder group relies on high-interest debt, posing risks of additional collateral demands or forced sales if the stock price falls, pressuring existing shareholders.
Several executives and shareholders including Oh Sejin, Jo Junghee, Han Woomin, Kwon Soongil, Sung Kwangjin, and Kwon Hyukjung resigned or changed, resulting in the cancellation of 0.42 million stock options. This suggests management instability, reducing potential dilution in the short term but raising concerns about long-term governance.
[AI Comprehensive Analysis]The decrease in stake and large-scale collateral pledge by the largest shareholder group reflect financial strain, and the high-interest debt structure could trigger cascading risks if the stock price declines. While early redemption removes convertible bond dilution, management uncertainty and debt burden cast a negative outlook on the stock.